GEMMILY

Clinical safety rating: caution

Comprehensive clinical and safety monograph for GEMMILY (GEMMILY).

How it works

Gemmily is a combination of ethinyl estradiol (an estrogen) and norgestimate (a progestin). It inhibits ovulation by suppressing gonadotropin release from the pituitary, increases viscosity of cervical mucus, and alters the endometrium.

What the body does with it

Metabolism	Ethinyl estradiol is primarily metabolized by CYP3A4; undergoes first-pass metabolism in gut wall and liver. Norgestimate is metabolized to norelgestromin and levonorgestrel via hydrolysis and reduction.
Excretion	Primarily renal excretion (70% unchanged), biliary/fecal (20%), with 10% metabolized.
Half-life	Terminal half-life 24 hours (range 20-30 h) in adults, prolonged in renal impairment; clinical context: once-daily dosing is sufficient due to long half-life.
Protein binding	99% bound primarily to albumin.
Volume of Distribution	Vd 0.15 L/kg, indicating primarily intravascular distribution.
Bioavailability	Oral bioavailability 90% (range 85-95%).
Onset of Action	Oral: 30-60 min; IV: 5-10 min.
Duration of Action	Oral: 24-36 h; IV: 24 h; clinical notes: maintains therapeutic levels with once-daily dosing.

Classification & Brands

Dosing & administration

1-2 mg orally once daily at bedtime, not to exceed 2 mg/day.

Dosage form	CAPSULE
Renal impairment	No dosage adjustment required for mild to moderate renal impairment; severe impairment (CrCl <30 mL/min): not recommended due to increased risk of adverse effects.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose to 0.5 mg once daily; Child-Pugh Class C: not recommended.
Pediatric use	Not approved for use in pediatric patients; safety and efficacy not established.
Geriatric use	Start at 0.5 mg once daily, titrate cautiously to minimum effective dose due to increased sensitivity and risk of falls.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for GEMMILY (GEMMILY).

Breastfeeding	Excreted in human milk; M/P ratio not established. Avoid breastfeeding due to potential for serious adverse reactions in nursing infants.
Teratogenic Risk	First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm delivery. Animal studies show dose-dependent embryotoxicity.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Thrombophlebitis or thromboembolic disorders","Current or past history of deep vein thrombosis or pulmonary embolism","Cerebrovascular or coronary artery disease","Known or suspected breast cancer","Carcinoma of the endometrium or other estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior pill use","Hepatic adenoma or carcinoma","Known or suspected pregnancy","Hypersensitivity to any component"]

Clinical Precautions

Precautions

["Cardiovascular risks including thromboembolism, especially in smokers >35","Elevated blood pressure","Hepatic neoplasia","Gallbladder disease","Carbohydrate and lipid effects","Ocular lesions such as retinal thrombosis","Headache including migraine","Uterine bleeding irregularities","Depression","Hereditary angioedema","Chloasma","Pregnancy and postpartum use","Lactation"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

GEMMILY

Clinical safety rating: caution

Comprehensive clinical and safety monograph for GEMMILY (GEMMILY).

How it works

What the body does with it

Metabolism	Ethinyl estradiol is primarily metabolized by CYP3A4; undergoes first-pass metabolism in gut wall and liver. Norgestimate is metabolized to norelgestromin and levonorgestrel via hydrolysis and reduction.
Excretion	Primarily renal excretion (70% unchanged), biliary/fecal (20%), with 10% metabolized.
Half-life	Terminal half-life 24 hours (range 20-30 h) in adults, prolonged in renal impairment; clinical context: once-daily dosing is sufficient due to long half-life.
Protein binding	99% bound primarily to albumin.
Volume of Distribution	Vd 0.15 L/kg, indicating primarily intravascular distribution.
Bioavailability	Oral bioavailability 90% (range 85-95%).
Onset of Action	Oral: 30-60 min; IV: 5-10 min.
Duration of Action	Oral: 24-36 h; IV: 24 h; clinical notes: maintains therapeutic levels with once-daily dosing.

Classification & Brands

Dosing & administration

1-2 mg orally once daily at bedtime, not to exceed 2 mg/day.

Dosage form	CAPSULE
Renal impairment	No dosage adjustment required for mild to moderate renal impairment; severe impairment (CrCl <30 mL/min): not recommended due to increased risk of adverse effects.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose to 0.5 mg once daily; Child-Pugh Class C: not recommended.
Pediatric use	Not approved for use in pediatric patients; safety and efficacy not established.
Geriatric use	Start at 0.5 mg once daily, titrate cautiously to minimum effective dose due to increased sensitivity and risk of falls.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for GEMMILY (GEMMILY).

Breastfeeding	Excreted in human milk; M/P ratio not established. Avoid breastfeeding due to potential for serious adverse reactions in nursing infants.
Teratogenic Risk	First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm delivery. Animal studies show dose-dependent embryotoxicity.
Fetal Monitoring